Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1โ€“36
Headlines
169
Sources here
1
Companies here
2
Current section Switzerland Capital Markets news
Latest

finance.yahoo.com Earnings

Starlink Launch Puts Globalstar Stock And Satellite Internet Shares In Focus

Space-based communications just had a spotlight moment as SpaceX's Starship carried a fresh batch of Starlink satellites into orbit, and that test has many investors rethinking what satellite internet exposure really means. This surge in attention can create openings where prices move faster than understanding. This article unpacks that story and profiles 3 stocks tied to the same โ€ฆ

Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Read at finance.yahoo.com
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
Just inNext headlines
finance.yahoo.com Macro sensitivity Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

3 Bond Trading Platform Stocks Getting Attention As Yields Reset

Bond markets have just yanked the spotlight away from equities, with Australia's 10 year yield hovering near a 15 year high around 5.5% and AI driven expectations reshaping how investors think about long term growth, inflation, and risk free returns. That kind of reset โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Gecina (ENXTPA:GFC), What Is Drawing Fresh Attention Now?

Gecina (ENXTPA:GFC) has drawn investor attention after recent trading left the stock flat on the day but down over the past month and the past 3 months, prompting closer scrutiny of its โ‚ฌ4.7b valuation. That weaker short term momentum, with a 7 day share โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

A Top Novartis (NVS) Shareholder Says โ€˜The Party is Overโ€™ for its Dealmaking Team

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)' 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker's board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Failure of Novartisโ€™ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

Novartis AG's (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca's โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

European Markets Close Lower in Thursday Trading as Bond Yields, Oil Prices Rise

The European stock markets closed lower in Thursday trading as bond yields and oil prices surged whi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?

Vertex Pharmaceuticals Incorporated VRTX has established a dominant position in the cystic fibrosis (CF) market through its portfolio of CFTR modulators, including Trikafta/Kaftrio and the newer Alyftrek. Vertex's marketed CF therapies are currently used by nearly three-quarters of the approximately 97,000 people with CF โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis Pharmaceuticals IONS announced positive results from two partnered programs, both of which are in phase III development. IONS Secures Phase III Win in ALS The first study, called FUSION, evaluated ulefnersen for the treatment of patients with amyotrophic lateral sclerosis (ALS) caused by โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAutologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Macro sensitivity Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

3 Integrated Oil And Gas Stocks Tied To Iran Supply Risk

Geopolitics around Iran have moved from background noise to front-page risk, and that shift is rippling through global integrated oil and gas producers. When conflict risk, energy supply questions and election politics collide, pricing for crude and related stocks can swing hard, creating both โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Macro sensitivity Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Creatio Invests $300 Million in Its Bank.AI Platform to Drive AI Adoption in Financial Services

BOSTON, Sept. 22, 2026 /PRNewswire/ -- Creatio, an AI CRM and workflow platform where people and AI agents work together, today announced a $300 million investment from 2026 through 2028 in Creatio Bank.AI, its market-leading offering for banks and financial institutions. The investment comes โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Spain Heatwave Puts Solaria Stock In Focus For Climate Adaptation Investors

Spain's record heat, wildfires, and drought are no longer distant headlines. They are starting to reshape where capital feels safe and where it looks more exposed. That shift creates a live question for your portfolio: Which Spanish stocks could benefit from climate adaptation spending, โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First

Company Logo Orphan drug demand is rising as genomics, biologics and personalized therapies advance, aided by faster approvals, government incentives, advocacy and improved rare-disease diagnosis. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global license agreement with Novartis Pharma AG ("Novartis") โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial

Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving 251 patients with early-stage ALS. The drug targeted TREM2, a protein involved โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthritis drug Cosentyx (secukinumab). The CHMP recommended Cosentyx for the treatment โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Capital return Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Melexis: update on the share buy-back program

Melexis N.V. Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium โ€“ 21 September 2026, 17.45 hrs CET Melexis reports the purchase of 14,519 Melexis shares on Euronext Brussels in the period from 14 September 2026 to 18 September โ€ฆ

CFTE mentioned CFT mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash

Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. Continue Reading

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Covivio (ENXTPA:COV) Could Be 24% Undervalued On Recent Share Price Weakness

Covivio (ENXTPA:COV) has drawn fresh attention after recent share price weakness, with the stock down about 9% over the past month and 11% over the past 3 months. That recent slide comes after a weaker run overall, with the share price down year to โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

What does the EU have that the U.S. does not?

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns. Still guessing which names to buy? Our AI rebuilds its โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Edison (BIT:EDNR) Shares Dropped, So What Is Driving Attention Now?

Edison (BIT:EDNR) traded at โ‚ฌ1.894 at the last close, with the share price lower over the past day, week, month, past 3 months and year to date. That recent slide in Edison's share price adds to a weaker short term trend, although the 1-year โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform

Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier. The transaction expands Novartis' toolkit for research into central nervous โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Gossan Resources Announces Changes to Board and Management

WINNIPEG, MB / ACCESS Newswire / September 18, 2026 / Gossan Resources Limited (GSS-TSX.V)(GSR-Frankfurt/Freiverkehr & Xetra) (the "Company" or "Gossan") is pleased to announce that the Board of Directors has appointed Kevin Norberg as interim Chief Executive Officer and Director, effective September 18, 2026. โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

4 Biotech Stocks to Watch as Potential Takeover Targets

M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-stage assets. For some companies, looming patent expirations are also โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Guidance Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption, while therapeutic agents and radiotheranostics are key growth segments. North America holds the largest โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis receives positive CHMP opinion for Cosentyxยฎ in polymyalgia rheumatica (PMR)

Novartis Pharma AG If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroidsยน Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years

On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1. It marked the company's third clinical setback โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too

On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS) and Ionis (IONS)โ€™ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

RAMSAY SANTE Group unveils "Connecting Care 2030"

RAMSAY SANTE PRESS RELEASE Paris, 17 September 2026 Ramsay Santรฉ Group unveils "Connecting Care 2030" to drive next phase of profitable growth and create long term value for all stakeholders "Connecting Care 2030", Ramsay Santรฉ Group's new strategic roadmap, leverages the transformation achieved through โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process. Continue Reading

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Trialynx Wins Forgeโ€™s DPHARM Idol Disrupt 2026

Forge BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2026 event. DPHARM is a part of Forge's Fierce Life Sciences. "DPHARM Idol โ€ฆ

CFTE mentioned
Sharemaestro market context Price below Trend Line 52 weeks -11.3% CFTE stored weekly price path from 3 Oct 2025 to 25 Sep 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context